Author Archives: Lu Rahman

#Biopharmaceuticals #Biotechnology #Mammalian transient protein #Pharmaceutical

Mammalian transient protein expression market players eye opportunities in biopharma

Global mammalian transient protein market revenues are projected to surpass US$ 540 million in 2020, according to a new study by Future Market Insights. The report also states that, innovations in automation and recombinant proteins will support market developments, however, prohibitive costs and complexity to maintain media purity remain challenges. Read More

#Market Reports #News

#Events #RNA

Event focusses on targeting RNA

Targeting RNA is set to be the next big thing; 85% of human genome transcribed to RNA but only 3% translated into proteins, therefore making it an obvious target. With Risdiplam being approved by the FDA in August, and several major collaborations also being penned throughout 2020, including a $190… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Moderna doses first participants in Phase II/III COVID-19 vaccine in adolescents

Moderna has announced that the first adolescent participants have been dosed in the Phase II/ III study of mRNA-1273, its vaccine candidate against COVID-19, in adolescents ages 12 to less than 18. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA), part of… Read More

#Covid-19 #News #Trending News

Accurate affinity profiling of a SARS-CoV-2 antibody in serum

The ability to accurately characterise the immune response against SARS-CoV-2 is of vital importance in managing the current COVID-19 pandemic. Measuring antibody affinity under physiologically relevant conditions in complex mixtures like serum remains challenging but is critically important to furthering our understanding of the immune response and protection window in… Read More

#Resources

#Immuno-oncology #Mouse models #Oncology

Syngeneic mouse models for preclinical immuno-oncology

The advent of immuno-oncology has necessitated changes in the types of animal models used in oncology drug discovery. Syngeneic models—inbred mice bearing an engrafted tumour derived from a genetically identical mouse strain—are invaluable preclinical research tools that enable tumor studies in the context of a complete and functional immune system. Read More

#Resources

#Covid-19 #Immunology / Virology & Vaccines

Novavax appoints vaccine industry expert to Board of Directors

Novavax has appointed Margaret McGlynn, to its board as an independent director. She has extensive pharmaceutical industry, vaccine and non-profit experience to her role on the Novavax Board of Directors. “Margie’s deep experience in vaccine commercialisation and understanding of global public health will be invaluable as we move closer to… Read More

#Covid-19 #News

#AMR #CDMO #Covid-19 #Immunology / Virology & Vaccines #RNA

Vaccine nationalism, AMR & CDMO expansion ahead for 2021

The new CPhI report looks ahead to a post-pandemic 2021 with pharma manufacturing capacity and payment structures shifting as new sourcing strategies emerge. It explores the potential implications in 2021 of impending vaccine approvals, a new administration in the White House and a return to dual supply chain strategies. The report… Read More

#Business & Investment #Covid-19 #Editor's Choice #Market Reports #News

#Covid-19 #Immunology / Virology & Vaccines

Less than half of people currently willing to get a COVID-19 vaccine, international survey suggests

A new report on the public’s attitudes towards coronavirus vaccines has revealed that around half of those surveyed (51%) may be willing to get vaccinated next year. Findings from a survey of 13,500 people across 15 countries* in November suggest that fewer would be willing if a vaccine were to… Read More

#Covid-19 #Editor's Choice #News

#Clinical trials #Covid-19 #Immunology / Virology & Vaccines

UC Davis Health joins Novavax in testing new COVID-19 vaccine

Despite the encouraging news of potentially successful COVID-19 vaccine trials, there is not yet an FDA-approved vaccine available. Research into other effective coronavirus vaccines continues, including at UC Davis Health. The health system is expected to launch a stage III clinical trial with the National Institutes of Health (NIH) and… Read More

#Covid-19 #News

#Clinical trials #Covid-19 #Vaccines

The ethics of human challenge trials

Rutgers Research Professor, Daniel Hausman, examines the ethical questions around human challenge trials for COVID-19 vaccines The first human challenge trial to test COVID-19 treatments and vaccines is set to begin in January in the United Kingdom. These trials, in which healthy volunteers are infected with the virus after being… Read More

#Covid-19 #Editor's Choice #News #Opinion

#Antibodies #Therapeutics

Evotec and Sartorius partner with start-up focussed on therapeutic exosomes

Evotec and Sartorius have teamed up with recently established Curexsys, a German technology leader specialising in the emerging field of therapeutic exosomes. Curexsys delivers a proprietary isolation technology for exosomes based on a traceless immune-affinity process. This process is different from commonly used antibody-based processes and enables the company to… Read More

#News

#Covid-19 #Immunology / Virology & Vaccines

Oxford vaccine: latest efficacy results released

University of Oxford and AstraZeneca researchers have released a pooled analysis of Phase III trials of a vaccine against SARS-CoV-2 across two different dose regimens, resulting in an average efficacy of 70.4%. The new study published in the Lancet is the first peer-reviewed publication of Phase III data from studies of… Read More

#Covid-19 #News #Trending News

#Toxicology

Gentronix expands toxicology services to meet growing global demand

UK-based Contract Research Organisation (CRO) Gentronix – a specialist toxicology CRO based at Alderley Park – is expanding its service range to provide specialist services in the field of dermal toxicology, amidst increasing global demand that is driving further growth for the business. Gentronix’s comprehensive development and growth strategy has… Read More

#News

#CAR-T #Oncology #Therapeutics

CAR T-cell therapy highly effective in patients with high-risk non-Hodgkin lymphoma

A CAR T-cell therapy known as axicabtagene ciloleucel (axi-cel) drove cancer cells to undetectable levels in nearly 80% of patients with advanced non-Hodgkin lymphoma (NHL) in a Phase III clinical trial, Dana-Farber Cancer Institute investigators report at the virtual 62nd American Society of Hematology (ASH) Annual Meeting. While… Read More

#Cancer Research #News #Videos

#Assay development & optimisation #Drug discovery

Event for assay developers, screening scientists and drug discovery research scientists

We understand the importance of kinetic assay design. In the upcoming DDW collaboration, supported by SPT Labtech, Dr Nick Holliday, Chief Scientific Officer, Excellerate Bioscience, will share his pharmacology expertise to explain how to produce assays that deliver hits with higher physiological relevance. Due to popularity we have opened up… Read More

#Editor's Choice #News